| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CSAG1 |
| Uniprot No | Q6PB30 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-78aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSDQVDWSRLYRDTGLVKMSRKPRASSPF SNNHPSTPKRFPRQPKREKGPVKEVPGTKGSP |
| 预测分子量 | 9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **CSAG1重组蛋白** 的3篇参考文献示例(注：部分内容基于模拟文献信息整理，实际文献需通过学术数据库验证)：
---
1. **文献名称**: *"Recombinant CSAG1 protein as a novel biomarker for melanoma progression"*
**作者**: Zhang Y, et al.
**摘要**: 该研究通过重组CSAG1蛋白的体外表达和纯化，验证其在黑色素瘤患者血清中的高表达水平，并发现其与肿瘤转移和免疫逃逸相关。重组CSAG1可激活特定T细胞反应，提示其作为免疫治疗靶点的潜力。
2. **文献名称**: *"Structural and functional characterization of recombinant CSAG1 in cancer-testis antigen family"*
**作者**: Lee S, Kim JH.
**摘要**: 通过大肠杆菌系统表达并纯化重组CSAG1蛋白，解析其三维结构，发现其具有独特的抗原表位。实验表明，重组CSAG1在多种癌细胞中特异性表达，并可能通过调控细胞周期促进肿瘤生长。
3. **文献名称**: *"CSAG1 recombinant protein-based ELISA for early detection of cervical cancer"*
**作者**: Gupta R, et al.
**摘要**: 开发了一种基于重组CSAG1蛋白的ELISA检测方法，用于宫颈癌患者血液样本的诊断。结果显示，重组CSAG1的敏感性和特异性显著优于传统标志物，支持其作为非侵入性诊断工具的潜力。
---
**备注**：以上文献信息为模拟生成，实际研究中建议通过 **PubMed、Web of Science** 或 **Google Scholar** 检索关键词“CSAG1 recombinant protein”获取最新文献。CSAG1作为癌症/睾丸抗原(CT antigen)家族成员，相关研究多聚焦于肿瘤免疫治疗和诊断领域。
**Background of CSAG1 Recombinant Protein**
The CSAG1 (Cancer/Testis Antigen Subfamily G1) protein, also known as CSAG2 or CTA2. is a member of the cancer-testis antigen (CTA) family, which is characterized by restricted expression in normal tissues (primarily in the testis and placenta) but aberrant overexpression in various malignancies. CTAs like CSAG1 are of significant interest in cancer research due to their tumor-specific expression, making them potential targets for immunotherapy and diagnostic biomarkers.
CSAG1 is encoded by a gene located within the major histocompatibility complex (MHC) class I region on chromosome 6p21.3. Its expression is epigenetically regulated, often reactivated in cancers through demethylation of promoter regions. The protein is implicated in tumorigenesis, with roles in promoting cell proliferation, evasion of apoptosis, and metastasis. Studies suggest its involvement in modulating cytoskeletal dynamics and stress response pathways, though its exact molecular mechanisms remain under investigation.
Recombinant CSAG1 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells*) to produce purified, biologically active forms for research applications. This recombinant tool enables studies on CSAG1's functional roles, antigenicity, and interactions with immune cells. It is particularly valuable in developing cancer vaccines, monoclonal antibodies, or T-cell therapies targeting CSAG1-positive tumors. Additionally, it aids in serological assays to detect CSAG1-specific autoantibodies in patient sera, supporting cancer diagnosis and prognosis.
Despite its promise, challenges include understanding CSAG1's pleiotropic functions and optimizing its immunogenicity for therapeutic use. Ongoing research aims to validate its clinical relevance and exploit its tumor-specific expression for precision oncology.
×
